These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 28774839)

  • 1. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
    Hashiba K; Sato Y; Harashima H
    J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
    Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
    J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
    Sato Y; Matsui H; Sato R; Harashima H
    J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
    Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
    J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.
    Sato Y; Note Y; Maeki M; Kaji N; Baba Y; Tokeshi M; Harashima H
    J Control Release; 2016 May; 229():48-57. PubMed ID: 26995758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes.
    Bao Y; Jin Y; Chivukula P; Zhang J; Liu Y; Liu J; Clamme JP; Mahato RI; Ng D; Ying W; Wang Y; Yu L
    Pharm Res; 2013 Feb; 30(2):342-51. PubMed ID: 22983644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
    Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
    Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.
    Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H
    J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.
    Sato Y; Okabe N; Note Y; Hashiba K; Maeki M; Tokeshi M; Harashima H
    Acta Biomater; 2020 Jan; 102():341-350. PubMed ID: 31733331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
    Suzuki Y; Ishihara H
    Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
    Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
    Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
    Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
    Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
    Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
    Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
    Cheng X; Lee RJ
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-PEGylation of siRNA Lipo-oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-Targeted Delivery.
    Müller K; Kessel E; Klein PM; Höhn M; Wagner E
    Mol Pharm; 2016 Jul; 13(7):2332-45. PubMed ID: 27177200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of an in vitro assay to screen lipid based nanoparticles for siRNA delivery.
    Zhang Y; Arrington L; Boardman D; Davis J; Xu Y; DiFelice K; Stirdivant S; Wang W; Budzik B; Bawiec J; Deng J; Beutner G; Seifried D; Stanton M; Gindy M; Leone A
    J Control Release; 2014 Jan; 174():7-14. PubMed ID: 24240015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
    Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
    Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
    Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
    J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.